We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough Enables Manipulation of the Chlamydia Genome

By LabMedica International staff writers
Posted on 14 Nov 2011
A team of microbiologists and molecular biologists believes that they have achieved a breakthrough in the study of Chlamydia genetics that could pave the way for the development of new treatments and possibly of a vaccine for this sexually transmitted disease.

Chlamydia trachomatis is a major human pathogen for which investigators have failed in attempts to manipulate genetically its DNA. More...
It is an obligate intracellular bacterium, which has a complex developmental cycle that takes place in a specialized host cell cytoplasmic vacuole known as an inclusion. The extracellular infectious elementary body (EB) is an infectious, electron-dense structure that, following host cell infection, differentiates into a noninfectious replicative form known as a reticulate body (RB).

In a paper published in the September 22, 2011, online edition of the journal PLoS Pathogens investigators at the University of Southampton (United Kingdom) and Ben Gurion University of the Negev (Be’er Sheva, Israel) reported that they had achieved a significant breakthrough in accessing the chlamydial genome.

This feat was accomplished by isolating penicillin resistant Chlamydia that were then treated with calcium chloride (CaCl2). Penicillin prevented the maturation of RBs into EBs. Instead, the RBs failed to divide although DNA replication continued. The investigators exploited these observations to develop a transformation protocol based on expression of beta-lactamase. They constructed a vector that carried both the chlamydial endogenous plasmid and a replication plasmid of E. coli origin so that the vector could shuttle between these two bacterial recipients. Proof of the method was obtained by insertion of the gene for a fluorescent protein into C. trachomatis, which identified chlamydial-infected cells by making them glow green.

"This is a very significant advance in the study of Chlamydia and we are proud to be the first people to achieve this,” said senior author Dr. Ian Clarke, professor of molecular microbiology at the University of Southampton. “Previously people have been unable to study chlamydial genetics, and this has created a barrier to the comprehensive study of this disease. We, together with our colleagues in Israel, discovered that by treating the Chlamydia with calcium ions we were able to introduce a piece of foreign DNA. This will open up the field of Chlamydia research and will enable a better understanding of chlamydial genetics. It could lead to the development of new approaches to chlamydial vaccines and therapeutic interventions.”

Related Links:
University of Southampton
Ben Gurion University of the Negev



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.